Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB
JIMD Reports · 2026-05 · 67 (3)
DOI: 10.1002/jmd2.70088 ↗Kurz gefasst
Fachartikel in der Zeitschrift JIMD Reports, online erschienen am 13.04.2026. Verfasst von Mark Wijnen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases Erasmus Medical Center Rotterdam the Netherlands. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mucopolysaccharidosis Type IV is a multisystem lysosomal storage disease characterized by severe skeletal dysplasia resulting from impaired degradation of the glycosaminoglycans keratan sulfate and chondroitin‐6‐sulfate. The condition is classified into Types A and B based on the underlying enzyme deficiency. Low bone mineral density (BMD) is a feature of the skeletal phenotype, contributing to increased fracture risk. Extraskeletal manifestations include, among others, cardiovascular disease due to valvular stenosis and regurgitation, myocardial remodeling, coronary artery disease, and vascular stiffness, all associated with glycosaminoglycan accumulation. We report two adult patients with mucopolysaccharidosis Type IVB treated with the osteoanabolic agent teriparatide for an apparently low BMD. The first patient presented with a non‐healing femoral fracture requiring BMD improvement prior to surgical fixation. This patient was treated with teriparatide for 2 years, which resulted in significant BMD gain, enabling successful surgical fixation. The second patient received teriparatide for only 6 months and showed stable BMD. Notably, both patients developed serious cardiac problems during teriparatide treatment: the first patient experienced rapidly progressive aortic stenosis, while the second patient developed dyspnea and polyuria due to worsening dynamic left ventricular outflow tract obstruction, which had previously been asymptomatic. Both patients required invasive cardiac interventions, which carry high risk in mucopolysaccharidosis due to unique anatomical and anesthetic challenges. The temporal association between teriparatide treatment and the onset of cardiac problems in both patients is noteworthy and raises the possibility of a treatment‐related effect. Therefore, we recommend cautious use of teriparatide in patients with mucopolysaccharidosis Type IV.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases Erasmus Medical Center Rotterdam the Netherlands.
- Department of Internal Medicine, Section Endocrinology, Erasmus MC Bone Center Erasmus Medical Center Rotterdam the Netherlands.
- Department of Cardiology Admiraal de Ruyter Hospital in Goes, Vlissingen, and Zierikzee the Netherlands.
- Department of Pediatrics, Center for Lysosomal and Metabolic Diseases Erasmus Medical Center Rotterdam the Netherlands.
- Laboratory for Calcium and Bone Metabolism, Department of Internal Medicine Erasmus Medical Center Rotterdam the Netherlands.
ORCID-Profile: Esmee Oussoren
Zitieren
APA
Wijnen, M., van Velsen, E. F. S., Milhous, J. G., Oussoren, E., van der Eerden, B. C. J., & Wagenmakers, M. A. E. M. (2026). Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB. JIMD Reports, 67(3). https://doi.org/10.1002/jmd2.70088
Vancouver
Wijnen M, van Velsen EFS, Milhous JG, Oussoren E, van der Eerden BCJ, Wagenmakers MAEM. Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB. JIMD Reports. 2026;67(3). doi:10.1002/jmd2.70088
BibTeX
@article{Wijnen2026,
author = {Wijnen, Mark and van Velsen, Evert F S and Milhous, J Gert-Jan and Oussoren, Esmee and van der Eerden, Bram C J and Wagenmakers, Margreet A E M},
title = {Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB},
journal = {JIMD Reports},
year = {2026},
volume = {67},
number = {3},
doi = {10.1002/jmd2.70088}
}
EUVIMED